Trials / Completed
CompletedNCT03618472
Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells
Effect of Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells : a Randomized Double Blind Placebo-controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand · Other Government
- Sex
- Female
- Age
- —
- Healthy volunteers
- Accepted
Summary
Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.
Detailed description
Endometrial cancer is one of the most common gynecological cancers. Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. The investigators tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in endometrial cancer. However, no good quality of evidence base supports the effectiveness of metformin for deceasing proliferative marker in endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin Hydrochloride 850 MG | Regular strength metformin (850 mg/tab) |
| DRUG | Placebo Oral Tablet | Starch based placebo manufatured to mimic Metformin 850 mg |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2019-11-30
- Completion
- 2020-01-30
- First posted
- 2018-08-07
- Last updated
- 2024-12-03
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03618472. Inclusion in this directory is not an endorsement.